Date:   6/26/2003 1:07:59 AM ( 21 y ago)
Hits:   12,864
URL:   https://www.curezone.org/forums/fm.asp?i=1046

0 of 0 (0%) readers agree with this message.  Hide votes     What is this?

"Home | Search | Browse | Resources | Help | What's New | About
Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer
This study is currently recruiting patients.
Sponsored by
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
Purpose
RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. CT-guided radiofrequency ablation may be effective treatment for lung cancer.
PURPOSE: Phase II trial to study the effectiveness of radiofrequency ablation in treating patients who have refractory or advanced lung cancer.
Condition Treatment or Intervention Phase
recurrent non-small cell lung cancerRecurrent Small Cell Lung Cancerrecurrent malignant mesotheliomarecurrent malignant thymomastage IIIB non-small cell lung cancerstage IV non-small cell lung cancerpulmonary carcinoid tumorlung metastases Procedure: hyperthermia Procedure: radiofrequency ablation Phase II
MEDLINEplus related topics: Asbestos/Asbestosis; Cancer (General); Cancer Alternative Therapy; Cancer--Living with Cancer; Carcinoid Tumors; Endocrine Diseases (General); Lung Cancer; Respiratory Diseases (General); Thymus Cancer
Study Type: Interventional
Study Design: Treatment
Official Title: Phase II Study of Radiofrequency Ablation in Patients With Refractory or Advanced Pulmonary Malignancies
Further Study Details:
OBJECTIVES:
 Determine the safety and toxicity of radiofrequency ablation in patients with refractory or advanced pulmonary malignancies.
 Determine the efficacy of this treatment, in terms of local control, in these patients.
 Determine whether CT scan is a reasonable imaging assessment tool for treatment delivery and follow-up in these patients.
OUTLINE: Patients undergo percutaneous CT-guided radiofrequency ablation directly to the tumor over 2 hours.
Patients are followed at 1, 3, 6, and 12 months.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
Eligibility
Genders Eligible for Study: Both
Criteria
DISEASE CHARACTERISTICS:
 Diagnosis of a primary or secondary intrathoracic malignancy
 Any cell type or origin
 Involving the intrapulmonary, mediastinal, or pleural/chest wall
 Inoperable primary or metastatic cancer to the lung
 Refractory to or not amenable to conventional therapy (e.g., surgery, chemotherapy, or radiotherapy)
 Single or multiple lesions that are non-contiguous with vital structures or organs such as:
 Trachea
 Heart
 Aorta
 Great vessels
 Esophagus
 Less than 5 cm in largest dimension
 Accessible via percutaneous transthoracic route
PATIENT CHARACTERISTICS: Age:
 Not specified
Performance status:
 Not specified
Life expectancy:
 Not specified
Hematopoietic:
 Not specified
Hepatic:
 Coagulation profile normal
Renal:
 Not specified
PRIOR CONCURRENT THERAPY:
 See Disease Characteristics

Location and Contact Information

California
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, 90095-1781, United States; Recruiting
Robert D. Suh, MD 310-794-2168

Study chairs or principal investigators

Robert D. Suh, MD, Study Chair, Jonsson Comprehensive Cancer Center
More Information
Study ID Numbers CDR0000068889; UCLA-9908024; NCI-G01-2011
Record last reviewed September 2001
NLM Identifier NCT00024076
ClinicalTrials.gov processed this record on 2003-06-24

U.S. National Library of Medicine, Contact NLM Customer Service
National Institutes of Health, Department of Health & Human Services
Copyright, Privacy, Accessibility, Freedom of Information Act"

Good Luck


 

<< Return to the standard message view

fetched in 0.03 sec, referred by http://www.curezone.org/forums/fmp.asp?i=1046